Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2018; 72(6): 551–552. doi:10.14735/amgh2018551.

First biosimilar adalimumab – SB5

Milan Lukáš Orcid.org  1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Lee N, Lee JJ, Yang H et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs 2018; 1–16. doi: 10.1080/19420862.2018.1530920.
2. Frampton JE. SB5: An adalimumab biosimilar. BioDrugs 2018; 32 (5): 507–510. doi: 10.1007/s40259-018-0307-0.
3. Weinblatt ME, Baranauskaite A, Dokoupilova E et al. Switching from reference adalimumab to SB5 (Adlimumab biosimilar) in patients with reumatoid arthritis: fifty-two-week phase 3 randomized study results. Arthritis Rheumatol 2018; 70 (6) : 832– 840. doi: 10.1111/ irv.40444.

Print

Credited self-teaching test

Start test

Most Read (last 6 month)

  1. Colorectal cancer screening in the Czech Republic
  2. Pancreatic cancer surveillance in high-risk individuals Position statement of professional societies
  3. Trends in premature mortality from digestive system cancers in Slovakia in the years 2011–2020: 8 diagnoses over 10 years
  4. Results from the evaluation of colorectal cancer screening in the Czech Republic
  5. Mixed adenoneuroendocrine carcinoma of the stomach – a case report
  6. Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity
  7. Urolithiasis in patients with inflammatory bowel disease – possibilities of prevention and metabolic influence
  8. Subcutaneous infliximab – treatments and new possibilities after clinical practice